Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer

3 Jun 2024

Abstract excerpt

Triple negative breast cancer (TNBC) remains exceptionally challenging to treat. While CDK4/6 inhibitors have revolutionized HR + breast cancer therapy, there is limited understanding of their efficacy in TNBC and meaningful predictors of response and resistance to these drugs remain scarce. We conducted an in vivo genome-wide CRISPR screen using palbociclib as a selection pressure in TNBC. Hits were prioritized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38831405
DOI: 10.1186/s12943-024-02029-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancerPMID 38831405Read ↗

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor ResistanceSemantic proximity Read ↗

Acquired resistance to CDK4/6 inhibition is associated with dysregulation of multiple pathways including cyclin D-CDK4/6-RB, EGFR/HER, AKT/mTOR and IFN signalingSemantic proximity Read ↗

Integrative analysis of scRNA-seq, spatial transcriptomics, and machine learning constructs a prognostic model for Pyrotinib resistance in breast cancerSemantic proximity Read ↗

BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathwaysSemantic proximity Read ↗

TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanismsSemantic proximity Read ↗

RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cellsSemantic proximity Read ↗

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer.Semantic proximity Read ↗

Clinically Translatable Approaches of Inhibiting TGF-β to Target Cancer Stem Cells in TNBCSemantic proximity Read ↗

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancerSemantic proximity Read ↗

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in CancerSemantic proximity Read ↗

CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicitySemantic proximity Read ↗

Rational design of HER2-targeted combination therapies to reverse drug resistance in fibroblast-protected HER2+ breast cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.